By Joe Hoppe
ImmuPharma PLC said Wednesday that its U.S. partner for its Lupuzor lupus treatment hasn’t yet received a written response concerning development and review from the U.S. Food and Drug Administration, due to general delays.
The London-li… [797 chars]
ImmuPharma Says US Partner Hasn’t Had Written Response From FDA Over Lupuzor
